Expression of complement regulator proteins in primary and metastatic malignant melanoma

Journal of Cutaneous Pathology

Volumn 26, Issue 5, 1999, Pages 217-221

  Weichenthal, Michael ^a   Siemann, Ute ^b   Neuber, Karsten ^b   Breitbart, Eckard W ^c  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Buxtehude Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; PROTEIN S 100; REGULATOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTIC NEVUS; MELANOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, NEOPLASM; CHILD; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS, PIGMENTED; S100 PROTEINS; SKIN NEOPLASMS;

EID: 0033018077     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1999.tb01833.x     Document Type: Article

References (26)

1. 1. Yamakawa M, Yamada K, Tsuge T, et al. Protection of thyroid cancer cells by complement regulatory factors. Cancer 1994; 73: 2808.
2. 2. Vogel CW. Complement, a biologic effector mechanism for tumor cell killing. In: Octigen HF, ed. Immunology and Allergy Clinics of North America. Human Cancer Immunology II, Vol.11. Philadelphia: W.B. Saunders, 1991; 277.
3. 3. Matsumoto M, Takeda J, Inoue N, et al. A novel protein that participates in nonself discrimination of malignant cells by homologous complement. Nat Med 1997; 3: 1266.
4. 4. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Ann Rev Immunol 1989; 7: 35.
5. 5. Saya T, Atkinson JP. Functional properties of membrane cofactor protein of complement. Biochem J 1989; 264: 581.
6. 6. Kojima A, Iwata K, Seya T, et al. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement-mediated C3-fragment deposition and cytolysis. J Immunol 1993; 151: 1519.
7. 7. Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170: 637.
8. 8. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000 20,000 MW complement lysis restriction factor, inhibits C5b-8 catalysed insertion of C9 into bilipid layers. Immunology 1990; 71: 1.
9. 9. Holguin MH, Fredrick LR, Bernshavv NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84: 7.
10. 10. Bjorge L, Vedeler, CA, Ulvestad E., Matre R. Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 1994; 24: 1597.
11. 11. Hakulinen J, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 1994; 71: 820.
12. 12. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70: 14.
13. 13. Simpson KL, Jones A, Norman S, Holmes CH. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol 1997; 151: 1455.
14. 14. Jarvis GA, Li J, Hakulinen J, et al. Expression and function of the complement membrane attack complex inhibitor protein (CD59) in humane prostate cancer. Int J Cancer 1997; 71: 1049.
15. 15. Sayama K, Shiraishi S, Miki Y. Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms. Br J Dermatol 1992; 127: 1.
16. 16. McNearny T, Ballard L, Seya T, Atkinson JP. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J Clin Invest 1989; 84: 538.
17. 17. Brasoveanu LI, Altomonte M, Gloghini A, et al. Expression of protectin (CD59) in human melanoma and its functional role in cell-and complement-mediated cytotoxicity. Int J Cancer 1995; 61: 548.
18. 18. Brasoveanu LI, Fonsatti E, Visintin A, et al. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J Clin Invest 1997; 100: 1248.
19. 19. Minasian LM, Yao TJ, Steffens TA, et al. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-oolony stimulating factor in patients with metastatic melanoma. Cancer 1995; 75: 2251.
20. 20. Cheung NK, Walter EI, Smith-Mensah WH, Rastnoff WD, Tykocinski ML, Medof ME. Decay-accelerating factor protects human tumor cell from complement-mediated cytotoxicity in vitro. J Clin Invest 1988; 81: 1122.
21. 21. Junnikkala S, Hakulinen J, Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol 1994; 24: 611.
22. 22. Brasoveanu LI, Altomonte M, Fonsatti E, et al. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 1996; 74: 33.
23. 23. Ollert MW, Frade R, Fiandino A, et al. C3-cleaving membrane proteinase. A new complement regulatory protein on human melanoma cells. J Immunol 1990; 144: 3862.
24. 24. Deckert M, Kubar J, Zoccola D, et al. CD59 molecule: a second ligand for CD2 in T-cell adhesion. Eur J Immnnol 1992; 22: 2943.
25. 25. Bjorge L, Skeie Jensen T, Ulvestad E, Vedeler CA, Matre R. The influence of tumour necrosis factor-a, interleukin-1b and interferon-g on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29. Scand J Immunol 1995; 41: 350.
26. 26. Steffens TA, Bajorin DF, Houghton AN. Immunotherapy with monoclonal antibodies in metastatic melanoma. World J Surg 1992; 16: 261.